Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells

Background: The management of Philadelphia Chromosome-positive (Ph+) hematological malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs). However, these drugs do not induce leukemic stem cells death and their persistence may generate a disease relapse. Publishe...

Descripción completa

Detalles Bibliográficos
Autores principales: Massimino, Michele, Vigneri, Paolo, Stella, Stefania, Tirrò, Elena, Pennisi, Maria Stella, Parrinello, Laura Nunziatina, Vetro, Calogero, Manzella, Livia, Stagno, Fabio, Di Raimondo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658323/
https://www.ncbi.nlm.nih.gov/pubmed/34884309
http://dx.doi.org/10.3390/jcm10235606

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658323/
https://www.ncbi.nlm.nih.gov/pubmed/34884309
http://dx.doi.org/10.3390/jcm10235606

Ejemplares similares